Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce today a €5,1 million investment to expand its production capacity for HPAPIs on its Le Mans site (72 – France), to continue the site’s steady growth and strengthen Novasep’s position as a leading CDMO in the manufacture of innovative and targeted molecules for cancer treatment. 

This investment involves the addition of a new chemical synthesis workshop for HPAPIs which will be commissioned in late 2023 and will add a further 10 full-time jobs. Thanks to efficient and optimized manufacturing processes, the new workshop will offer production solutions reducing the impact on the environment. 

This new investment will support Novasep’s growth in the strategic market of ADCs. Boosted by a wave of recent approvals and supported by a robust clinical pipeline, ADC based drugs are now fulfilling their early promises and are firmly established as a cornerstone of cancer therapy. With more than 15 years of experience in the field of ADCs, the Novasep’s Le Mans site is recognized for its expertise in offering integrated solutions to produce ADC payloads and bioconjugation. 

Rachel De Luca, Director of the Le Mans site explains: “The production at Le Mans site offers unparalleled flexibility to produce ADC payloads at different scales and in complete safety. We are increasing our production capacity to support the development of tomorrow’s cancer drugs with agility, while enhancing the robustness of the supply chain of the commercial products of our historical customers.”